A. Azrilevich

发表

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Jun Zhu, C. Cordon-Cardo, W. Oh, 2018, Nature Communications.

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.

P. Sharma, P. Ott, J. Rosenberg, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

E. Plimack, M. Galsky, P. Sharma, 2017, The Lancet. Oncology.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

P. Sharma, F. D. De Braud, P. Ott, 2016, The Lancet. Oncology.

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Jun Zhu, M. Galsky, P. Sharma, 2018 .

848PDImpact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study

Matthew D. Galsky, Alexandre Lambert, C. Horak, 2017 .